months; hazards ratio (HR) 0.27, 95% confidence interval (CI): 0.17-0.42; P < 0.0001] and from the time of initial crizotinib treatment (median 29.6 versus 10.8 months; HR 0.30, 95% CI: 0.19-0.46; P < 0.0001). The multiple-covariate Cox regression analysis revealed that CBPD remained significantly associated with improved OS after adjusting for relevant factors.
Conclusions:
Patients who continued CBPD were more likely to have good ECOG PS (0/1) at the time of PD. Continuing ALK inhibition with crizotinib after PD may provide survival benefit to patients with advanced ALK-positive NSCLC. Key words: treatment beyond disease progression, crizotinib, TKI, RECIST, oncogene addiction, ALK-positive NSCLC introduction Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) is a heterogeneous molecular subtype of NSCLC with at least 27 ALK-fusion variants identified [1] [2] [3] . ALK kinase activity in ALK-positive NSCLC is aberrantly activated through dimerization of various fusion partners (EML4, KIF5B, KLC1, or TFG) in the cytoplasm. Crizotinib is a multitargeted small-molecule ALK inhibitor approved for the treatment of advanced ALK-positive NSCLC [4, 5] . In a randomized phase III trial, crizotinib demonstrated significantly improved progression-free survival (PFS) when compared with standardof-care chemotherapy for previously treated advanced ALKpositive NSCLC [6] .
Most patients with advanced ALK-positive NSCLC treated with crizotinib eventually develop progressive disease (PD), as observed in patients with epidermal growth factor receptor (EGFR)-mutation-positive (EGFRm) NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs). In patients with EGFRm NSCLC, EGFR TKI therapy is sometimes continued beyond the conventional radiographic definition of PD per Response Evaluation Criteria in Solid Tumors (RECIST) [7, 8] . Additionally, patients with EGFRm NSCLC may develop a disease flare manifested as either rapid radiographic PD or significant worsening of symptoms, including death, upon discontinuation of EGFR TKI therapy, indicating that EGFRm tumors continue to depend on EGFR signaling [9] . Disease flare following discontinuation of crizotinib in ALK-positive NSCLC has also been reported [10] . However, whether continuation of ALK inhibition with crizotinib beyond PD (CBPD) would also be beneficial to patients with ALK-positive NSCLC treated with crizotinib remains unknown.
Two ongoing single-arm studies of crizotinib in advanced ALK-positive NSCLC, the molecularly enriched expansion cohort of a phase I trial (PROFILE 1001) and a phase II trial (PROFILE 1005), allowed the continuation of crizotinib beyond RECIST-defined PD in patients who continued to derive clinical benefit from crizotinib. Camidge et al. [11] have described the feasibility and tolerability of continuing CBPD in 39 patients with advanced ALK-positive NSCLC. In this report, we carried out a retrospective analysis to investigate whether or not continuation of ALK inhibition with crizotinib is clinically beneficial and whether there are any clinicopathologic characteristics of patients with ALK-positive NSCLC who could potentially benefit from this approach.
patients and methods

patients and procedures
Patients with advanced ALK-positive NSCLC enrolled in either PROFILE 1001 expansion cohort or PROFILE 1005 (and treated by 1 February 2011 in the latter study) were included in this analysis (supplementary Figure S1 , available at Annals of Oncology online). ALK rearrangement was detected by break-apart FISH [4] . Key inclusion and exclusion criteria for PROFILE 1001 have been previously described [4, 11] . Key inclusion and exclusion criteria for PROFILE 1005 were similar to those of PROFILE 1001 [5] . Major differences included treatment setting: patients in PROFILE 1005 must have failed at least one line of treatment, while patients in PROFILE 1001 could have been treatment-naïve. Disease assessment was carried out every 6 (PROFILE 1005) or 8 weeks (PROFILE 1001). Response confirmation was required in both studies. PROFILE 1005, but not PROFILE 1001, required baseline brain imaging, and if brain metastases were detected, follow-up brain imaging was required. Otherwise, imaging to assess brain metastases was carried out as clinically indicated in both trials. In this analysis, PD was based on overall investigator assessment of tumor data and RECIST-defined, unless specifically noted. All patients received crizotinib at a starting dose of 250 mg twice daily with appropriate dosing modification as needed. Data collected at protocol-specified intervals that were the nearest, but prior, to the time of PD included performance status (PS), adverse events (AEs), and clinical laboratory tests. For CBPD patients, the same schedule of activities as that used before PD was followed for collection of AE data. A period of 3 weeks of treatment after first documentation of PD was chosen as the cut-off for defining continuing or not continuing CBPD (>3 versus ≤3 weeks, respectively) because it was within one treatment cycle for the majority of the patients, the time frame within which investigators generally decide whether or not to continue CBPD. Patients who had received crizotinib as first-line treatment in PROFILE 1001 were excluded from this analysis to ensure that comparable populations of patients from the two trials were analyzed. Patients from either study whose best overall response to initial crizotinib treatment was PD were also excluded from this analysis since inclusion of these patients could confound the comparison of post-PD survival in patients who did or did not continue CBPD. These patients are highly unlikely to benefit from continuation of CBPD and are more likely to fall into the group that did not continue CBPD, thereby biasing the analysis. All patients provided written informed consent before initial study entry and Institutional Review Board (IRB) approved the protocols. The data cut-off date for this analysis was 2 January 2012.
survival analysis
The Kaplan−Meier method was used to estimate all time to tumor progression (TTP) and overall survival (OS) endpoints. Two-sided 95% confidence intervals (CIs) were determined using the Brookmeyer-Crowley method. The Cox proportional hazards models with multiple covariates were used to assess the impact of continuing CBPD on OS from the first dose of crizotinib and from the time of PD with adjustment for various potential confounding factors, retaining statistically significant factors after model selection (factors analyzed are listed in supplementary Data, available at Annals of Oncology online, along with additional details about the methodology). The hazard ratios (HRs) between the two groups were estimated using the Cox proportional hazard models with 95% Wald CIs. All analyses were carried out using SAS statistical software, version 9.2 (SAS Institute Inc., Cary, NC). Figure S1 , available at Annals of Oncology online). A total of 194 patients who had developed PD by the time of data cut-off constituted the final study population. One hundred and twenty patients (62%) continued crizotinib for >3 weeks post-PD, while 74 patients (38%) did not continue crizotinib beyond 3 weeks post-PD at the discretion of the investigators. The median duration of follow-up post-PD for the 120 patients who continued CBPD was 25.2 weeks (range 3.7-115.9). Baseline and post-progression characteristics of these patients are provided in Table 1 . The groups were comparable in age at baseline, proportions of patients from the two trials, smoking history, histology, and prior treatment history. The only significant difference between the two groups was the PS at the time of PD (Table 1) . Among patients with Eastern Cooperative Oncology Group PS (ECOG PS) of 0 or 1 at the time of PD, 65% (115/176) continued CBPD. On the other hand, among patients with ECOG PS of ≥2 at the time of PD, only 29% (4/14) continued CBPD.
We carried out an analysis of the sites of PD to investigate whether or not the brain may be a common site of PD in patients who continued CBPD. In the absence of standard minimum tumor growth criteria defining individual sites of PD when there are multiple sites of progressing target lesions, we analyzed the subset of patients who had PD involving new lesions and/or non-target lesions (N = 138). Among these patients, half of the patients (51%) who continued CBPD had brain as a site of PD, while patients who did not continue CBPD had both liver (37%) and brain (28%) as a site of PD (supplementary Table S1 , available at Annals of Oncology online).
responses to initial crizotinib treatment
Maximum percentage reductions from baseline in target lesions among both groups of patients while on crizotinib treatment are shown in supplementary Figure S2 , available at Annals of Oncology online. In all, 97% of patients in both groups had some tumor shrinkage. CBPD patients had a numerically higher objective response rate to initial crizotinib treatment (74%, 95% CI 65-82) than did patients who did not continue CBPD (55%, 95% CI 43-67), although this difference was not significant, as the 95% CIs overlapped (Table 2) . Among patients who achieved RECIST-defined complete response (CR) or partial response (PR) to initial crizotinib treatment, 68% (89/130) continued CBPD. Among patients who achieved SD as best response to initial crizotinib treatment, 48% (31/64) continued CBPD. Among patients who maintained SD for ≥6 months on initial crizotinib treatment, 70% (16/23) continued CBPD. The median TTP from initial crizotinib treatment for the entire patient group was 6.9 months (95% CI 6.2-7.9). The median TTP from initial crizotinib treatment was numerically longer among patients who continued CBPD (7.3 months, 95% CI 6.8-8.9) than among those who did not continue CBPD (5.7 months, 95% CI 5.4-6.8), although the 95% CIs overlapped (Table 2) .
treatment duration beyond PD
The median duration of crizotinib treatment post-PD (total number of active dosing days from first PD to last dose) among the 120 CBPD patients in this analysis was 19.4 weeks (95% CI 16.7-28.9). The duration of CBPD was comparable between patients who received crizotinib as second-line treatment (n = 27; 20.7 weeks, 95% CI 11.9-29.6) and those who received crizotinib as third-or later-line treatment (n = 93; 19.4 weeks, 95% CI 16.0-32.0). Among the 74 patients who did not continue CBPD, 37 (50%) received subsequent systemic treatment, and the remaining 37 (50%) received best supportive care only.
survival analysis
The median OS for the overall population from the time of PD was 8.9 months (95% CI 7.2-16.4; Table 2 ). The median OS from the time of PD was significantly longer for CBPD patients than for patients who did not continue CBPD [16.4 months (95% CI 14.5-not reached) versus 3.9 months (95% CI 2.7-5.1); HR 0.27, 95% CI 0.17-0.42; P < 0.0001; Figure 1A ]. Six-and 12-month survival probabilities after PD for CBPD patients were 76.3% (95% CI 66.7-83.5) and 64.7% (95% CI 53.0-74.3), respectively, compared with 6-and 12-month survival probabilities of 31.2% (95% CI 20.0-43.0) and 23.9% (95% CI 13.3-36.1), respectively, for patients who did not continue CBPD.
A possible reason for the survival disadvantage seen among patients who did not continue CBPD was that a subset of these patients never received further anticancer therapy post-PD. To address this, we evaluated the impact of receiving or not receiving subsequent systemic anticancer treatment in this group. The median OS post-PD among patients who did not continue crizotinib but received subsequent systemic therapy (n = 37; 5.4 months, 95% CI 3.8-12.3) was longer than that of those who did not continue crizotinib and received no subsequent therapy (n = 37; 2.2 months, 95% CI 1.1-3.8; Figure 1B) . Nevertheless, the median OS of patients who did not continue crizotinib but received subsequent systemic therapy remained significantly shorter than that of CBPD patients (5.4 versus 16.4 months; HR 0.38, 95% CI 0.22-0.66; P = 0.0005).
The median OS for the overall population (n = 194) was 21.9 months (95% CI 16.6-not reached) from the start of initial crizotinib treatment ( Table 2 ). The median OS from the start of initial crizotinib treatment was significantly longer for CBPD patients than for patients who did not continue crizotinib [29.6 months (95% CI: 23.1-not reached) versus 10.8 months (95% CI: 8.9-14.7); HR 0.30, 95% CI: 0.19-0.46; P < 0.0001; Figure 1C ].
After adjusting for potential confounding factors (supplementary Data, available at Annals of Oncology online), continuing CBPD remained significantly associated with improved OS post-PD (HR 0.27; P < 0.0001; Table 3 ). Both response (CR/PR) to initial crizotinib treatment (HR 0.48; P = 0.01) and longer TTP (HR 0.78; P = 0.01) were also found to be factors associated with improved OS (Table 3) . Eight patients (all did not continue CBPD) died ≤3 weeks after PD documentation. After adjusting for potential confounding factors and analyzing the 186 patients 
discussion
Molecularly targeted therapy is increasingly being continued beyond PD, especially in cancers harboring an underlying oncogenic dependence on the molecular target, such as trastuzumab in HER2-positive breast cancer [12, 13] and EGFR TKIs in EGFRm NSCLC [14] . In the present retrospective analysis, we showed that patients with advanced ALK-positive NSCLC derived clinical benefit from continued ALK inhibition with crizotinib after RECIST-defined PD. These patients were more likely to have good PS at the time of PD, had responded to and exhibited extended TTP from initial crizotinib treatment, and had a site of PD particularly amenable to local therapy (brain). Not surprisingly, these patients also had a better prognosis as demonstrated by their longer OS from the start of initial crizotinib treatment ( Figure 1C ). While it may seem intuitive that 24 (18) 19 (21) 5 (12) 16 to <24 weeks, n (%) 9 (7) 5 (6) 4 (10) ≥24 weeks, n (%)
5 (4) 4 (4) patients who derive clinical benefit on initial crizotinib treatment benefit from continued ALK inhibition with crizotinib, our report represents the largest systematic collection of the clinicopathologic data from these patients to date and shows, reassuringly, that continuation of ALK inhibition with CBPD was practiced by many of the investigators in the two trials. ALK-positive NSCLC is a heterogeneous disease with many EML4-ALK fusion variants that likely present a diverse clinical picture and may exhibit differential responses to crizotinib and other ALK inhibitors [15] . Several crizotinib resistance mechanisms have been reported, including generation of secondary resistance mutations, amplification of the ALK gene, and activation of other bypass signaling pathways [16] [17] [18] [19] . However, the resistance mechanism is unknown in the majority of the patients whose disease progressed on crizotinib due to low frequency of re-biopsy, especially when the progressing metastatic lesions occur in the brain which are not easily amenable to biopsy.
There are limitations to the present retrospective analysis despite efforts to adjust for confounding factors by the Cox regression analysis with multiple covariates and to exclude patients who did not respond at all to initial crizotinib treatment. While there were no gross imbalances in the clinicopathologic characteristics of the two groups of patients analyzed, there may be unknown confounding factors not considered in our analysis. Therefore, the ability to continue CBPD could simply represent a subgroup with favorable prognostic factors rather than a direct post-PD treatment effect. Data on the use of ALK inhibitors other than crizotinib, subsequent disease progression while on continued CBPD, the type of chemotherapy regimen used after PD, and the mode of any radiation therapy delivered to patients with PD on crizotinib were not captured.
As CBPD is not expected to provide clinical benefit indefinitely, other strategies such as the addition of local therapy [20] , sequencing chemotherapy [21] , or addition of HSP90 inhibitors [22] to CBPD should be evaluated prospectively in this treatment setting. Furthermore, several ALK inhibitors are in clinical development primarily for PD after crizotinib [23] [24] [25] . Given the potential survival benefit in ALK-positive NSCLC patients who continue CBPD reported herein, direct comparative studies between these newer ALK inhibitors versus CBPD plus additional treatment modalities would be needed to inform optimal treatment after PD on crizotinib.
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